News Room

Plexus Ventures Assists Celon Pharma to Out-License Generic Advair® Diskus® for France

January 19, 2017

London, United Kingdom - Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for France.

Michael O’Sullivan, Managing Partner (London), the Plexus Ventures partner responsible for the project, commented: “We are extremely pleased we were able to help our client succeed in this project. This was a complex transaction requiring significant time and energy from all parties involved. We have shown once again that our persistence leads to success even in the most challenging assignments.”


About Plexus Ventures

Now in its 27th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading pharmaceutical companies worldwide.